Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT 1 COMBINATION PACK versus NYSTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT 1 COMBINATION PACK versus NYSTATIN.
MONISTAT 1 COMBINATION PACK vs NYSTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and leads to fungal cell death. Miconazole also has direct anti-inflammatory and antibacterial properties.
Nystatin binds to sterols in the fungal cell membrane, primarily ergosterol, altering membrane permeability and causing leakage of intracellular components, leading to fungal cell death.
Miconazole nitrate 1200 mg vaginal suppository inserted intravaginally once at bedtime; plus external miconazole nitrate 2% cream applied to affected area twice daily for up to 7 days.
Oral: 500,000 to 1,000,000 units (5-10 mL suspension) swish and swallow 3-4 times daily; Vaginal: 1 vaginal tablet (100,000 units) once or twice daily; Topical: Apply cream/ointment 2-3 times daily; duration depends on indication.
None Documented
None Documented
Clinical Note
moderateNystatin + Tranilast
"The risk or severity of adverse effects can be increased when Nystatin is combined with Tranilast."
Clinical Note
moderateNystatin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Nystatin is combined with Tolfenamic acid."
Clinical Note
moderateNystatin + Nimesulide
"The risk or severity of adverse effects can be increased when Nystatin is combined with Nimesulide."
Clinical Note
moderateNystatin + Risedronic acid
Terminal elimination half-life: 24-30 hours (range 20-50 hours). Clinical context: Once-daily dosing may be considered for some indications, but prolonged half-life supports weekly or twice-weekly regimens for systemic infections.
Due to minimal systemic absorption, a terminal elimination half-life is not clinically relevant. In vitro plasma degradation half-life is approximately 1.5 hours, but this is not applicable in vivo.
Fecal: Approximately 90% of absorbed dose; Renal: <2% as unchanged drug; Biliary: Minor, less than 10%.
Nystatin is not absorbed from the gastrointestinal tract after oral administration; virtually 100% of the ingested dose is excreted unchanged in the feces. After topical application, systemic absorption is negligible; any absorbed drug is excreted via bile and feces (<1% renal).
Category C
Category A/B
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Nystatin is combined with Risedronic acid."